FFAR3/GPR41 Antibody (2590G) [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # FAB10562M
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry, Western Blot
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Recombinant Monoclonal Rabbit IgG Clone # 2590G
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Synthetic peptide containing human FFAR3
Specificity
Detects human FFAR3 in direct ELISAs.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Applications for FFAR3/GPR41 Antibody (2590G) [DyLight 594]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from cell culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: FFAR3/GPR41
Long Name
Free Fatty Acid Receptor 3
Alternate Names
FFA3, FFA3R, GPR41
Additional FFAR3/GPR41 Products
Product Documents for FFAR3/GPR41 Antibody (2590G) [DyLight 594]
Product Specific Notices for FFAR3/GPR41 Antibody (2590G) [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...